Foradil, Formoterol News

Main Category: Respiratory / Asthma Also Included In: Medical Devices / Diagnostics In two recent COPD studies sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors were used to show that nebulized formoterol fumarate improves pulmonary function.

Mylan Inc. sued Teva Pharmaceutical Industries Ltd. to prevent it from selling a generic version of the Perforomist inhaler for people with chronic bronchitis and emphysema.

SkyePharma PLC today announces that the US Food and Drug Administration has issued a communication in respect of the New Drug Application for its lead development product, FlutiformTM , an investigational treatment for persistent asthma in patients 12 years of age and older.

COPD, or chronic obstructive pulmonary disease, is a respiratory disease affecting thousands of people every year.

A major allergy and respiratory management company knowingly produced flawed clinical trials of FDA approved drugs currently on the market a Texas physician is charging.

Preliminary results from a double-blind, randomised, multicentre trial among 660 patients with chronic obstructive pulmonary disease show that budesonide/formoterol plus tiotropium significantly improves disease control and patients' quality of life.1,2 The study known as CLIMB, compared 12 weeks treatment with budesonide/formoterol plus tiotropium ...

The Novartis investigational bronchodilator QAB149 met the primary efficacy endpoints of improved lung function compared to placebo at 12 weeks in three pivotal phase III studies in chronic obstructive pulmonary disease patients.

Data presented at this year's American Thoracic Society congress, demonstrated that SYMBICORT added to SpirivaTM provided greater clinical improvements than tiotropium alone over a 12-week treatment period.1,2 Results of the CLIMB study showed that the occurrence of severe exacerbations was reduced by as much as 62 percent in patients where ...

BASEL,A Switzerland Early results of a phase 3 trial have shown that an investigational treatment for chronic obstructive pulmonary disease can improve lung function within five minutes of the first dose.

Novartis ' investors can breathe a little easier. The company's new treatment for chronic obstructive pulmonary disease -- a.k.a. "smoker's lung" -- passed its three phase 3 trials without so much as a cough.

Flutiform NDA Accepted for Review LONDON, UK, 22 May 2009 - SkyePharma PLC today announces that the New Drug Application for its lead development product, Flutiform , an investigational treatment for persistent asthma in patients 12 years of age and older, has been accepted for review by the US Food and Drug Administration .

Swiss pharmaceutical company Novartis AG Thursday released positive phase-III study data for its smoker's cough drug QAB149.

Posted 01:00 AM ET KENILWORTH, N.J., May 19, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease .

The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Novartis assumes exclusive worldwide development and marketing rights for investigational once-daily QMF149 being developed for COPD and asthma * QMF149 combines QAB149 with mometasone and is ...

Dey, L.P., a subsidiary of Mylan Inc. , announced today that data from two presentations highlighting the use of Perforomist Inhalation Solution will be featured in poster format at the International Conference of the American Thoracic Society on May 19, 2009 in San Diego.

AN INHALER with budesonide and formoterol , which has served as an asthma drug for several years, is now approved to treat chronic obstructive pulmonary disease .

Balancing the Benefits and Risks of Inhaled Long-Acting Beta-Agonists - The Influence of Values Judith M. Kramer, M.D., M.S. In December 2008, the Food and Drug Administration convened a joint meeting of the Pediatric Advisory Committee, the Pulmonary-Allergy Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee to ...

Traditionally inhaled treatment for asthma has been considered as preventer and reliever therapy.

People suffering from chronic asthma might have a new treatment option that allows them to manage their condition with a single prescribed inhaler that contains two medicines, according to a new review.

Main Category: Respiratory / Asthma Also Included In: Pharma Industry / Biotech Industry AstraZeneca announced the company has received a Complete Response Letter from the US Food and Drug Administration for SYMBICORT pressurized metered dose inhaler for the long-term maintenance treatment of asthma in paediatric patients ages 6-11 years.